The surface of the bubbles contains an agent that distinguish enables cancer cells from healthy.

This technology enables cancer treatment drugs tiny bubbles tiny bubbles so small that millions along a single inch fit. The surface of the bubbles contains an agent that distinguish enables cancer cells from healthy. ‘ ‘recognize ‘a cancer cell, they deliver the medication they carry to the cell.. Nausea more troubling other health risks due to the damage that the drug does to the immune system of the patient are Called ‘drug carriers ‘recent reports of Prof. Margalit’s new technology in both cancer and osteoarthritis therapies were used in Nature Nanotechnology and in the Journal of Controlled Release published .

– This trend is on the leading edge of the new frontier of drug delivery and treatment of cancer, says Prof. Margalit. Bubble technology can also be used for other medical conditions, including diabetes, arthritis, wounds and infections. Twenty years from now it could be widespread. .. And infections. Cells onlyFor millions of Americans with cancer, the side effects of chemotherapy and other treatments can be devastating drug. But new drug-delivery research into nano-and microtechnology from Tel Aviv University is based could much needed relief and more effective treatment of cancer. Developing new drug delivery technology by Prof. Rimona Margalit of Tel Aviv University Department of Biochemistry and allow drugs to cancer cells, so that the surrounding healthy cells intact and reducing the painful side effects of chemotherapy -.WHO: Anthony S. Director of, National Institute for Allergy and Infectious Diseases and chief, NIAID Laboratory immune regulation and Susan moire, Staff Scientist, NIAID Laboratory immune regulation.

NIAID is a component of out of to the National Institutes of Health. NIAID supports basic and applied research to prevent, diagnose and treatment of infectious disease such as HIV / AIDS and other sexually transmitted diseases, tuberculosis, malaria and illness from the potential agents of bioterrorism. NIAID also supports research about basic immunology, transplant and immune-related disorders, including autoimmune diseases, asthma and allergy.